News

Invitae has launched a new genetic testing program, at no charge to participants, to test adults suspected of having — or at risk of developing — neurodegenerative disorders, including Parkinson’s disease. The Adult Neurodegenerative Disorders sponsored testing…

Exercise can slow early cognitive decline in Parkinson’s disease patients who have a variant of the APOE gene, called APOE4, a recent study has found. “Additional research is needed to confirm our findings, but these results would support the use…

New research suggests that brain inflammation is the likely reason antibody-based therapies are ineffective in clinical trials for people with Parkinson’s and Alzheimer’s diseases. The findings show that the binding of the antibody to its target protein — in the case of Parkinson’s disease the misfolded alpha-synuclein —…

Microbleeds found in the brains of people with Parkinson’s disease by magnetic resonance imaging (MRI) scans were associated with cognitive decline, a study demonstrated.  Higher levels of a microbleed-associated biomarker also were found in patients with dementia. Moreover, a statistical analysis found the…

Inbrain Neuroelectronics has raised  $16.8 million in Series A financing to support moving into clinical testing a new neuromodulation device that uses computer learning to treat Parkinson’s disease and epilepsy. Electrodes for this next-generation neurostimulator are also based on graphene, a single layer of tightly bound carbon  atoms that allows…

A Parkinson’s Foundation indoor cycling event aimed at highlighting the benefits of exercise while raising money for Parkinson’s (PD) research returns on June 12 for its second year. Called the Parkinson’s Revolution, the cycling program will take place at studios in 25 cities — up from…

Magnetic nanoparticles may help restore brain function by directing nerve cell growth, a new study shows. Researchers believe this technology has therapeutic potential and may be used in the development of new treatments for Parkinson’s disease, The study, “Magnetic spatiotemporal control of SOS1 coupled nanoparticles for guided neurite growth in…

Gocovri (amantadine) more than doubled the daily time on levodopa-based therapies without any dyskinesia — involuntary, uncontrolled movements — in people with Parkinson’s disease compared to those given a placebo, an analysis of data from two Phase…

In light of Parkinson’s Awareness Month — starting April 1st — Parkinson Canada is calling for better awareness of the neurodegenerative disorder, while supporting organizations dedicated to helping those impacted by it. This message is made more urgent by COVID-19, according to…

Activities are underway to mark Parkinson’s Awareness Month, set aside each April to draw attention to the neurodegenerative disorder that affects some seven to 10 million people globally. At the center of this observance is World Parkinson’s Day April 11. Patients, family, caregivers and friends across the country…